{"id":"hl-040xc","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5289060","moleculeType":null,"molecularWeight":"338.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HL-040XC is designed to bind and block inhibitory signals on T cells by targeting multiple immune checkpoint pathways simultaneously. This dual-targeting approach aims to overcome resistance mechanisms and generate more potent anti-tumor immunity compared to single-checkpoint inhibitors. The bispecific format allows coordinated engagement of both targets on the same molecule.","oneSentence":"HL-040XC is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:43.481Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT01541943","phase":"PHASE3","title":"Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2012-03","conditions":"Essential Hypertension, Hyperlipidemia","enrollment":356},{"nctId":"NCT01806324","phase":"PHASE1","title":"A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2012-04","conditions":"Hypertension, Hyperlipidemia","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HL-040XC","genericName":"HL-040XC","companyName":"HanAll BioPharma Co., Ltd.","companyId":"hanall-biopharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HL-040XC is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}